Form 4: Co-Diagnostics President Granted 220,000 RSUs

Co-Diagnostics, Inc. President Richard David Abbott was granted 220,000 Restricted Stock Units (RSUs) under the company's long-term incentive plan.

Summary

• Richard David Abbott, President of Co-Diagnostics, Inc. (CODX), was granted 220,000 Restricted Stock Units (RSUs).
• The grant occurred on August 13, 2025.
• These RSUs were issued under the Issuer's 2015 Long Term Incentive Plan, as amended.
• Each RSU represents the contingent right to receive one share of Co-Diagnostics' common stock upon vesting.
• The RSUs will vest in 6 installments, commencing on November 23, 2025, with subsequent installments every 6 months thereafter.
• Following this transaction, Richard David Abbott beneficially owns 350,438 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: The grant of RSUs to a key executive is generally positive as it aligns management's interests with shareholders and incentivizes long-term performance. It's a standard compensation practice, indicating stability in executive retention and a commitment to future value creation.

Positives

• The grant of 220,000 Restricted Stock Units to the President aligns management's interests with shareholder value creation.
• The vesting schedule over time encourages long-term commitment and performance from a key executive.

Negatives

• No direct negative financial implications are immediately apparent from this RSU grant, as it is a standard form of executive compensation.

Risks

• No specific risks were detailed in this Form 4 filing, as it primarily reports an executive compensation transaction.

Future Outlook

The filing indicates a future vesting schedule for the granted Restricted Stock Units, with installments commencing on November 23, 2025, and continuing every six months thereafter, tying executive compensation to future performance and tenure.

Industry Context

This RSU grant is a common practice in the biotechnology and diagnostics industry, used to attract, retain, and incentivize key executives by aligning their compensation with the long-term performance of the company's stock.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a standard practice across the biotechnology and broader corporate sectors, comparable to compensation structures at companies like Exact Sciences Corp. (EXAS) or QuidelOrtho Corporation (QDEL).
• The vesting schedule, typically over several years, is also consistent with industry norms designed to promote long-term executive retention and performance alignment.

Related Party Transactions

• The grant of Restricted Stock Units to Richard David Abbott, the President, constitutes a transaction with a related party (an executive officer).

Stakeholder Impact

• Shareholders: The RSU grant aligns the President's financial interests with the company's stock performance, potentially benefiting shareholders through improved long-term value.
• Employees: No direct impact on general employees is indicated, but it reinforces the company's executive compensation structure.
• Management: The President receives a significant equity award, incentivizing continued leadership and performance.

Next Steps

• The Restricted Stock Units will begin vesting in 6 installments, with the first installment on November 23, 2025, and subsequent installments every 6 months thereafter.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) and does not contain information significant enough to warrant a change in investment recommendation. It primarily indicates ongoing executive incentive alignment rather than new operational or financial performance data.

Keywords

Co-Diagnostics, CODX, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, SEC Form 4, Long Term Incentive Plan, Biotechnology, Diagnostics